Nevertheless, there is currently a lack of cost-effectiveness evidence assessing the use of iruplinalkib as a first-line therapy for the same indication.Crizotinib, the first targeted TKI for advanced ALK-positive (ALK+) NSCLC, was approved by the US Food and Drug Administration (FDA) in 2011 (FDA, 2023) and by the China National Medical Products Administration (NMPA) in 2013 (Liu et al., 2019). Here, ALK is linked to non-small cell lung carcinoma.